N05BB01 hydroxyzine

NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Diphenylmethane derivatives

健保收載品項 TFDA 在效許可證 3 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 3 張;以下列出 3 個品項(2 項有外觀照)。

健保收載品名:"信隆"欣得寧錠25毫克、"岳生"日樂斯糖衣錠10毫克(鹽酸亥多西任)、克胺寧錠25毫克(鹽酸亥多西任)、喜賜爽錠、得慮安膜衣錠25公絲、欣平定錠25毫克、維泰寧膠囊

無外觀照
維泰寧膠囊
克胺寧錠25毫克(鹽酸亥多西任) 外觀
克胺寧錠25毫克(鹽酸亥多西任)
圓形 · 白 · 刻痕:直線 · 標記:M M · 8 mm
"信隆"欣得寧錠25毫克 外觀
"信隆"欣得寧錠25毫克
圓形 · 紫 · 刻痕:直線 · 9.5 mm

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 焦慮狀態、嘔吐、過敏疾患。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 hydroxyzine hydrochloride (商品名 HYDROXYZINE HYDROCHLORIDE / Hydroxyzine Hydrochloride / Hydroxyzine Pamoate / Hydroxyzine hydrochloride / Hydroxyzine pamoate / hydroxyzine pamoate) · 仿單更新 2026-03-30

The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。